Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Get Quote
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Celcuity Inc. - Common Stock
(NQ:
CELC
)
12.92
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celcuity Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
May 08, 2023
Via
ACCESSWIRE
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
May 08, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
April 18, 2023
Via
ACCESSWIRE
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
Via
ACCESSWIRE
Celcuity's Earnings: A Preview
March 22, 2023
Via
Benzinga
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
September 14, 2022
Via
ACCESSWIRE
Celcuity: Q2 Earnings Insights
August 11, 2022
Celcuity (NASDAQ:CELC) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
March 16, 2023
Via
ACCESSWIRE
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
March 15, 2023
Via
ACCESSWIRE
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
March 01, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
February 16, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
January 05, 2023
Via
Benzinga
Celcuity Closes $100 Million Private Placement
December 12, 2022
Via
ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
December 09, 2022
Via
ACCESSWIRE
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 08, 2022
Via
Benzinga
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
December 07, 2022
Via
ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
November 22, 2022
Via
ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
November 10, 2022
Via
ACCESSWIRE
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
November 03, 2022
Via
ACCESSWIRE
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
Via
ACCESSWIRE
Earnings Outlook For Celcuity
August 10, 2022
Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will...
Via
Benzinga
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
August 04, 2022
Via
ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
Via
ACCESSWIRE
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
July 18, 2022
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million.
Via
Benzinga
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today...
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.